Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 78

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 78
---
 20 patent families that collectively contain 70 granted patents, 6 allowed patent applications and 73 pending
patent applications relating to the two candidates listed below. We are also pursuing patent protection for other drug candidates in our
pipeline. Patents related to our therapeutic candidates may provide future competitive advantages by providing exclusivity related to
the composition of matter, formulation, and method of administration of the applicable compounds and could materially improve the value
of our therapeutic candidates. The patent positions for our three therapeutic candidates are described below and include both issued patents
and pending patent applications we exclusively license. We vigorously defend our intellectual property to preserve our rights and gain
the benefit of our investment.

  The motixafortide drug product composition of matter and methods of manufacturing thereof are covered by                                         
  a granted U. S. patent and patent applications pending in the USA (two applications received notice of allowance). Israel, Europe, Japan,        
  Canada, Australia, China, India, Mexico, Brazil, Hong-Kong and Korea. The patents, if granted, will expire in December 2041, not including       
  any applicable patent term extension, which may add an additional term of up to five years for the U. S. patents. We also have an exclusive      
  license to a patent family that covers motixafortide combined with a PD1 antagonist for the treatment of cancer. Patents of this family          
  have been granted in the U. S., Israel, Australia, China, India, Mexico and Hong Kong; and member patent applications are pending in Australia,  
  Hong Kong, Europe, China, Canada, India, Israel and Brazil. The granted U. S. patent and patents to issue in the future based on pending         
  patent applications in this family will expire in 2036, not including any applicable patent term extension. In addition, we have an exclusive    
  license to nineteen other patent families pending or granted worldwide directed to methods of synthesis of motixafortide and methods of          
  use of motixafortide either alone or in combination with other drugs for the treatment of certain types of cancer and other indications.         
  Furthermore, we have Orphan Drug status for AML, pancreatic cancer and stem cell mobilization, as well as data exclusivity protection            
  afforded to motixafortide as an NCE.                                                                                                             
  The motixafortide drug product composition of matter and methods of manufacturing thereof are covered by                                         
  a granted U. S. patent and patent applications